Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alicaforsen enema in chronic antibiotic refractory pouchitis
NCT02525523Phase 3Completed
- Sponsor
- Atlantic Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Jul 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 10
01
Overview
A Phase 3 trial of alicaforsen in pouchitis, sponsored by Atlantic Pharmaceuticals. Started Dec 2015; status: completed.
02
Drugs
alicaforsen
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT02525523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525523.